Protagenic Historical Balance Sheet

PTIXW Stock  USD 0.01  0.01  80.00%   
Trend analysis of Protagenic Therapeutics balance sheet accounts such as Total Stockholder Equity of 6.1 M, Property Plant And Equipment Net of 117.2 K, Cash of 2 M or Non Current Assets Total of 117.2 K provides information on Protagenic Therapeutics' total assets, liabilities, and equity, which is the actual value of Protagenic Therapeutics to its prevalent stockholders. By breaking down trends over time using Protagenic Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Protagenic Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Protagenic Therapeutics is a good buy for the upcoming year.

Protagenic Therapeutics Inventory

284,050

  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

About Protagenic Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Protagenic Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Protagenic Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Protagenic Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Protagenic currently owns. An asset can also be divided into two categories, current and non-current.

Protagenic Therapeutics Balance Sheet Chart

At this time, Protagenic Therapeutics' Other Assets are fairly stable compared to the past year. Capital Stock is likely to climb to 758.80 in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 294.3 K in 2024.

Total Assets

Total assets refers to the total amount of Protagenic Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Protagenic Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Protagenic Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Protagenic Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Short Term Investments

Short Term Investments is an item under the current assets section of Protagenic Therapeutics balance sheet. It contains any investments Protagenic Therapeutics undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Protagenic Therapeutics can easily liquidate in the marketplace.
Most accounts from Protagenic Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Protagenic Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
At this time, Protagenic Therapeutics' Other Assets are fairly stable compared to the past year. Capital Stock is likely to climb to 758.80 in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 294.3 K in 2024.
 2021 2022 2023 2024 (projected)
Short and Long Term Debt Total318.4K344.2K309.8K294.3K
Total Assets11.1M8.0M4.3M4.1M

Protagenic Therapeutics balance sheet Correlations

0.020.54-0.150.630.58-0.020.190.080.570.570.72-0.48-0.480.71-0.20.570.68-0.12-0.170.880.12-0.24-0.240.81-0.27
0.02-0.090.88-0.70.360.76-0.8-0.080.370.36-0.31-0.41-0.41-0.260.870.37-0.160.790.89-0.180.940.830.83-0.18-0.35
0.54-0.09-0.330.530.64-0.210.420.20.640.640.12-0.58-0.580.7-0.40.640.21-0.39-0.340.32-0.03-0.44-0.450.08-0.36
-0.150.88-0.33-0.860.010.64-0.98-0.030.010.0-0.21-0.07-0.07-0.421.00.01-0.330.971.0-0.210.920.990.99-0.14-0.11
0.63-0.70.53-0.860.28-0.540.850.10.270.270.54-0.16-0.160.71-0.880.270.58-0.81-0.870.64-0.66-0.9-0.890.530.03
0.580.360.640.010.280.290.16-0.051.01.0-0.15-0.92-0.920.35-0.051.00.27-0.140.00.20.4-0.11-0.120.05-0.59
-0.020.76-0.210.64-0.540.29-0.55-0.690.310.31-0.31-0.42-0.42-0.310.650.310.00.540.66-0.230.680.610.61-0.06-0.43
0.19-0.80.42-0.980.850.16-0.55-0.030.160.170.11-0.13-0.130.37-0.980.160.34-1.0-0.980.15-0.84-0.99-0.990.09-0.07
0.08-0.080.2-0.030.1-0.05-0.69-0.03-0.07-0.090.170.220.220.21-0.06-0.07-0.140.05-0.040.23-0.02-0.03-0.03-0.060.39
0.570.370.640.010.271.00.310.16-0.071.0-0.16-0.94-0.940.33-0.041.00.27-0.140.00.180.4-0.1-0.110.05-0.62
0.570.360.640.00.271.00.310.17-0.091.0-0.16-0.95-0.950.31-0.051.00.28-0.150.00.170.39-0.11-0.120.04-0.64
0.72-0.310.12-0.210.54-0.15-0.310.110.17-0.16-0.160.210.220.59-0.22-0.160.56-0.05-0.220.91-0.21-0.22-0.210.940.21
-0.48-0.41-0.58-0.07-0.16-0.92-0.42-0.130.22-0.94-0.950.211.0-0.12-0.03-0.94-0.260.13-0.07-0.04-0.410.040.050.00.82
-0.48-0.41-0.58-0.07-0.16-0.92-0.42-0.130.22-0.94-0.950.221.0-0.12-0.03-0.94-0.260.13-0.07-0.04-0.410.040.050.00.82
0.71-0.260.7-0.420.710.35-0.310.370.210.330.310.59-0.12-0.12-0.460.320.37-0.31-0.430.74-0.2-0.48-0.490.520.14
-0.20.87-0.41.0-0.88-0.050.65-0.98-0.06-0.04-0.05-0.22-0.03-0.03-0.46-0.04-0.340.971.0-0.240.891.01.0-0.15-0.09
0.570.370.640.010.271.00.310.16-0.071.01.0-0.16-0.94-0.940.32-0.040.28-0.140.010.180.4-0.1-0.110.04-0.63
0.68-0.160.21-0.330.580.270.00.34-0.140.270.280.56-0.26-0.260.37-0.340.28-0.3-0.320.63-0.2-0.36-0.350.65-0.18
-0.120.79-0.390.97-0.81-0.140.54-1.00.05-0.14-0.15-0.050.130.13-0.310.97-0.14-0.30.97-0.070.840.980.98-0.020.09
-0.170.89-0.341.0-0.870.00.66-0.98-0.040.00.0-0.22-0.07-0.07-0.431.00.01-0.320.97-0.220.910.990.99-0.15-0.12
0.88-0.180.32-0.210.640.2-0.230.150.230.180.170.91-0.04-0.040.74-0.240.180.63-0.07-0.22-0.07-0.25-0.240.920.19
0.120.94-0.030.92-0.660.40.68-0.84-0.020.40.39-0.21-0.41-0.41-0.20.890.4-0.20.840.91-0.070.860.86-0.08-0.32
-0.240.83-0.440.99-0.9-0.110.61-0.99-0.03-0.1-0.11-0.220.040.04-0.481.0-0.1-0.360.980.99-0.250.861.0-0.16-0.04
-0.240.83-0.450.99-0.89-0.120.61-0.99-0.03-0.11-0.12-0.210.050.05-0.491.0-0.11-0.350.980.99-0.240.861.0-0.15-0.03
0.81-0.180.08-0.140.530.05-0.060.09-0.060.050.040.940.00.00.52-0.150.040.65-0.02-0.150.92-0.08-0.16-0.150.07
-0.27-0.35-0.36-0.110.03-0.59-0.43-0.070.39-0.62-0.640.210.820.820.14-0.09-0.63-0.180.09-0.120.19-0.32-0.04-0.030.07
Click cells to compare fundamentals

Protagenic Therapeutics Account Relationship Matchups

Protagenic Therapeutics balance sheet Accounts

201920202021202220232024 (projected)
Total Assets842.3K879.2K11.1M8.0M4.3M4.1M
Other Current Liab1.2M513.3K520.6K620.1K541.5K514.4K
Total Current Liabilities1.2M655.2K799.5K1.1M655.3K622.5K
Total Stockholder Equity(634.4K)(1.1M)9.9M6.9M3.7M6.1M
Property Plant And Equipment Net611.0296.00.01.8K123.3K117.2K
Net Debt(519.3K)702.7K(222.7K)129.0K(1.3M)(1.4M)
Retained Earnings(15.2M)(17.7M)(22.2M)(25.8M)(30.8M)(32.3M)
Cash798.6K671.1K541.2K215.2K1.3M2.0M
Non Current Assets Total611.0296.00.01.8K123.3K117.2K
Cash And Short Term Investments798.6K671.1K10.4M8.0M4.1M3.9M
Liabilities And Stockholders Equity842.3K879.2K11.1M8.0M4.3M4.1M
Non Current Liabilities Total52.4K279.4K1.4M318.4K1.0M0.0
Other Current Assets43.4K208.2K688.7K56.9K144.0K136.8K
Other Stockholder Equity14.7M16.7M32.4M33.4M34.6M41.2M
Total Liab1.5M2.0M1.1M1.1M655.3K622.5K
Total Current Assets842.0K879.2K11.1M8.0M4.2M7.5M
Accumulated Other Comprehensive Income(172.4K)(171.6K)(248.3K)(676.9K)(113.5K)(119.2K)
Accounts Payable36.2K141.9K279.0K155.5K113.8K108.1K
Net Invested Capital(355.0K)224.1K10.3M7.3M3.7M3.5M
Net Working Capital(355.3K)224.1K10.3M6.9M3.5M3.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.